Clare Cunliffe

Technology company SARB has partially succeeded in a challenge to a ruling that it infringed a rival’s intellectual property in its development of a parking system used by the City of Melbourne, with an appeals court finding a judge made an error in his reading of the claims of one patent at issue.

Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.

Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.

Tech company SARB has won a stay of orders barring it from selling its sensor-based system which the city of Melbourne uses for timing parked vehicles, after a judge found it infringed rival Vehicle Management Systems’ patent.

German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.

A judge has upheld findings from IP Australia that South Korean biotech ToolGen’s genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.

Novartis unit Sandoz has won its bid to stay a case by rival Lundbeck, including orders for damages previously calculated at $26.3 million and counting, despite having succeeded at the High Court in a dispute over its patent for blockbuster antidepressant Lexapro.

Tech company Vehicle Management Systems has won a long-running patent infringement dispute with rival SARB over a sensor-based system the City of Melbourne uses for timing parked vehicles. 

The defendants in a trade mark infringement case by the Pokemon Company were the victims of identity theft and were wrongly named in the suit, a court has heard.

German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.